Clinical Trial

Evaluation of Efficacy and Safety of Milsaperidone as Adjunctive Therapy in Patients With Major Depressive Disorder

Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The purpose of this study is to determine the efficacy and safety of milsaperidone compared to placebo as adjunctive therapy in patients with Major Depressive Disorder
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2025-02-11; most recent amendment 2026-02-25.
Status change: Not Yet Recruiting → Recruiting 2025-05-20
Trial Details
NCT Number NCT06830044
Lead Sponsor Vanda Pharmaceuticals
Conditions Major Depressive Disorder (MDD)
Enrollment 500 participants
Start Date 2025-03-03
Primary Completion 2028-03 (estimated)
Study Completion 2028-03 (estimated)
Updated on ClinicalTrials.gov 2026-02-27